ArticleCureus2025
Quality of Life of Lower Limb Lymphatic Filariasis Patients in a North Indian Tertiary Care Center: A Prospective Observational Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This observational study was carried out at a tertiary care facility in North India. A total of 154 patients with different degrees of lymphedema and clinically diagnosed lower limb lymphatic filariasis (LF; ages 15-75 years) were included. Seven dimensions of quality of life (QoL) were assessed using the Lymphatic Filariasis Specific Quality-of-life Questionnaire (LFSQQ; higher scores indicate a better overall QoL). There was a significant (p<0.001) difference in all the QoL domains among different grades. All QoL domains significantly worsened (p<0.001) among patients with disease grade III compared to grade I. However, pain/discomfort, psychological health, social participation, and total scores were significantly (p<0.001) lower among patients with disease grade III than II. The LFSQQ and overall QoL response were significantly different (p<0.001) among duration of disease groups and grades of disease. The study shows that LF has a significant negative effect on quality of life, especially in individuals who have a long-term illness and are in advanced stages of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.